Schwartzbach, Caryl J <br/><br/>
Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.  [electronic resource] 

 -  Journal of neurology  Feb 2017 
 - 304-315 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1432-1459 
<br/><br/><label>Standard No.: </label>10.1007/s00415-016-8341-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adult<br/>Benzazepines--adverse effects<br/>Brain--diagnostic imaging<br/>Double-Blind Method<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Glatiramer Acetate--administration & dosage<br/>Gray Matter--diagnostic imaging<br/>Histamine Antagonists--adverse effects<br/>Humans<br/>Injections, Intramuscular<br/>Interferon beta-1a--administration & dosage<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--diagnostic imaging<br/>Myelin Sheath--drug effects<br/>Neuroprotective Agents--adverse effects<br/>Single-Blind Method<br/>White Matter--diagnostic imaging<br/>Young Adult